CloudCath announced today that it completed a $12 million Series A financing round for its at-home dialysis monitoring treatment platform.
San Francisco–based CloudCath’s system, which is its first product, is designed to enable remote, real-time monitoring for people undergoing at-home peritoneal dialysis to allow for earlier complication intervention. Proceeds from the funding round are also earmarked for developing additional applications for CloudCath’s proprietary technology.
Differing from the current standard of care that relies on visual detection to identify infection origination, CloudCath’s system is designed to integrate into a person’s drain line, monitoring the spent dialysate fluid on every dialysis cycle by measuring and quantifying the fluid properties remotely from the user’s home.
Real-time data is then transmitted to the CloudCath cloud-based infrastructure for algorithms to notify healthcare providers when there is a potential complication. Healthcare providers are able to log into CloudCath’s monitoring platform to observe real-time data and influence treatment decision management.
CloudCath said its clinical advisory board projects a 75% reduction in infection-driven hospitalizations, thanks to the technology, with a potential reduction of $2.6 billion in the U.S. healthcare system’s annual spending on the issue.
“The CloudCath technology enables patients and caregivers to easily monitor fluid parameters for early signs of complications, including infection, in real-time, allowing dialysis providers to intervene much earlier than the existing standard of care,” CloudCath co-founder & CEO Aly ElBadry said in a news release. “This funding will speed commercialization of the CloudCath system, pending FDA clearance, and will also support our goal of offering remote monitoring for infectious disease management in multiple additional applications.”
Capital Integral led the $12 million funding round, while FundRx, The Capital Partnership, Coconut Tree Investments, Stanford University’s StartX Fund and additional investors participated.